Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sitagliptin + enalaprilat
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and enalaprilat, the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor enalapril. The interaction between these two classes of drugs was investigated by Vanderbilt University in a mechanistic clinical trial (NCT01202903) to determine if DPP-4 inhibition potentiates vasodilator responses during ACE inhibition. This research is particularly relevant to understanding the pathophysiology of ACE inhibitor-associated angioedema, as both ACE and DPP-4 are involved in the degradation of vasoactive peptides such as substance P and bradykinin. Sitagliptin is primarily indicated for the management of type 2 diabetes mellitus, while enalaprilat is used for the treatment of hypertension and heart failure.
- Brand names
- JanuviaVasotec
- Other names
- Sitagliptin and Enalaprilat InteractionDPP-4 inhibitor + ACE inhibitor combination
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on sitagliptin + enalaprilat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sitagliptin + enalaprilat.